10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $3.2B | $1.3B | 87.9% | 46.9% | $1.0B | — | $1.6B |
| 2024 | $2.9B | $1.2B | 89.2% | 47.9% | $1.1B | — | $1.7B |
| 2023 | $2.3B | $985M | 88.9% | 50.9% | $748M | — | $1.2B |
| 2022 | $1.9B | $727M | 92.2% | 50.6% | $664M | — | $961M |
| 2021 | $1.7B | $476M | 92.7% | 33.0% | $477M | — | $895M |
| 2020 | $1.5B | — | 92.7% | 40.0% | $696M | — | $739M |
| 2019 | $1.4B | — | 91.9% | -12.9% | -$290M | — | $738M |
| 2018 | $1.6B | — | 87.8% | 49.5% | $594M | — | $669M |
| 2017 | $1.7B | — | 93.9% | 47.2% | $388M | — | $705M |
| 2016 | $1.6B | — | 95.5% | 66.4% | $606M | — | $1.0B |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $782M | $275M | 82.9% | 41.7% | $363M | — | $1.3B |
| Dec '25 | $790M | $364M | 86.9% | 45.1% | $173M | — | $1.6B |
| Sep '25 | $800M | $339M | 87.4% | 48.6% | $352M | — | $1.3B |
| Jun '25 | $799M | $310M | 89.0% | 45.6% | $130M | — | $1.6B |
| Mar '25 | $794M | $322M | 88.4% | 48.2% | $386M | — | $1.9B |
| Dec '24 | $736M | $301M | 89.7% | 48.6% | $255M | — | $1.7B |
| Sep '24 | $749M | $309M | 88.9% | 45.8% | $301M | — | $1.6B |
| Jun '24 | $715M | $278M | 89.1% | 44.7% | $187M | — | $1.4B |
| Mar '24 | $678M | $307M | 89.2% | 52.6% | $338M | — | $1.3B |
| Dec '23 | $615M | $217M | 88.4% | 42.3% | $72M | — | $1.2B |
| Sep '23 | $609M | $268M | 88.5% | 53.7% | $281M | — | $1.1B |
| Jun '23 | $597M | $259M | 89.3% | 52.5% | $62M | — | $1.1B |
| Mar '23 | $507M | $241M | 89.7% | 56.1% | $334M | — | $1.2B |
| Dec '22 | $492M | $132M | 88.0% | 35.7% | $89M | — | $961M |
| Sep '22 | $516M | $239M | 92.8% | 60.9% | $190M | — | $967M |
| Jun '22 | $467M | $116M | 93.6% | 43.2% | $110M | — | $795M |
| Mar '22 | $462M | $240M | 94.4% | 62.4% | $275M | — | $813M |
| Dec '21 | $415M | $112M | 91.7% | 40.9% | $104M | — | $895M |
| Sep '21 | $445M | $163M | 93.8% | 51.4% | $162M | — | $909M |
| Jun '21 | $447M | $173M | 91.7% | 49.8% | $132M | — | $942M |
How the market has priced UTHR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, United Therapeutics Corp's revenue has grown 16.5% per year, and net income grown 29.4% per year. These are computed facts, not advice.
As of FY2025, United Therapeutics Corp reported — of total debt against $1.6B of cash; operating income covered interest expense 77×.
In FY2025, gross margin was 87.9%, operating margin 46.9%, and net margin 41.9%.
As of Jun '26, United Therapeutics Corp traded at a price-to-earnings ratio of about 17.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.